Express Scripts (NASDAQ:ESRX) has been given a $101.00 target price by research analysts at Mizuho in a report released on Monday. The brokerage currently has a “hold” rating on the stock. Mizuho’s target price would indicate a potential upside of 4.40% from the company’s current price.
ESRX has been the subject of a number of other reports. BidaskClub lowered shares of Express Scripts from a “hold” rating to a “sell” rating in a research note on Saturday, July 21st. ValuEngine upgraded shares of Express Scripts from a “hold” rating to a “buy” rating in a research note on Monday, September 17th. Credit Suisse Group downgraded shares of Express Scripts from an “outperform” rating to a “neutral” rating and raised their price target for the company from $90.00 to $96.50 in a report on Tuesday, September 18th. Royal Bank of Canada set a $101.00 price target on shares of Express Scripts and gave the company a “buy” rating in a report on Thursday. Finally, Leerink Swann set a $100.00 price target on shares of Express Scripts and gave the company a “hold” rating in a report on Thursday. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. Express Scripts presently has an average rating of “Hold” and a consensus target price of $89.07.
Shares of ESRX stock opened at $96.74 on Monday. The company has a quick ratio of 0.65, a current ratio of 0.77 and a debt-to-equity ratio of 0.63. Express Scripts has a 12-month low of $59.17 and a 12-month high of $98.98. The company has a market cap of $54.55 billion, a PE ratio of 13.63, a P/E/G ratio of 1.22 and a beta of 0.89.
Express Scripts (NASDAQ:ESRX) last issued its quarterly earnings results on Wednesday, October 31st. The company reported $2.43 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.42 by $0.01. Express Scripts had a net margin of 4.83% and a return on equity of 25.43%. The company had revenue of $25.56 billion during the quarter, compared to analyst estimates of $25.11 billion. During the same quarter last year, the business posted $2.51 EPS. Express Scripts’s quarterly revenue was up 3.6% compared to the same quarter last year. Equities analysts forecast that Express Scripts will post 9.08 earnings per share for the current fiscal year.
In other news, insider Christine Houston sold 12,898 shares of Express Scripts stock in a transaction on Friday, August 10th. The shares were sold at an average price of $85.00, for a total transaction of $1,096,330.00. Following the completion of the sale, the insider now directly owns 110,908 shares of the company’s stock, valued at approximately $9,427,180. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.79% of the stock is owned by company insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Gulf International Bank UK Ltd lifted its holdings in shares of Express Scripts by 9.4% during the 3rd quarter. Gulf International Bank UK Ltd now owns 196,137 shares of the company’s stock worth $18,634,000 after acquiring an additional 16,896 shares during the last quarter. WINTON GROUP Ltd lifted its holdings in shares of Express Scripts by 969.9% during the 3rd quarter. WINTON GROUP Ltd now owns 59,752 shares of the company’s stock worth $5,677,000 after acquiring an additional 54,167 shares during the last quarter. Gabelli Funds LLC lifted its stake in Express Scripts by 222.8% in the third quarter. Gabelli Funds LLC now owns 322,805 shares of the company’s stock worth $30,670,000 after purchasing an additional 222,805 shares during the last quarter. GABELLI & Co INVESTMENT ADVISERS INC. bought a new stake in Express Scripts in the third quarter worth $37,291,000. Finally, Gamco Investors INC. ET AL lifted its stake in Express Scripts by 337.8% in the third quarter. Gamco Investors INC. ET AL now owns 35,900 shares of the company’s stock worth $3,411,000 after purchasing an additional 27,700 shares during the last quarter. 84.20% of the stock is owned by institutional investors.
Express Scripts Company Profile
Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services.
Recommended Story: Intrinsic Value
Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with MarketBeat.com's FREE daily email newsletter.